ArticleAsian journal of transfusion science
Anti-hepatitis C virus antibody status and outcomes in serologic assays in blood donors.
Article in Asian journal of transfusion science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C virus (HCV) is a major issue in the field of blood transfusion safety and blood components. Serological tests are used to detect anti-HCV antibodies in blood donors. This study was performed to evaluate the status of anti-HCV antibodies in blood donors and serological assays. SUBJECTS AND
methodsData related to the results of screening and confirmation tests of 427,203 blood donors were examined over a 6-year period.
resultsThe results showed the highest frequency of positive ELISA results 329 (% 0.39) among first-time blood donors. Out of 901 samples with reactive/positive ELISA result, 104 (11.5%) samples had positive or IND confirmation test results which were belong to donors with a history of healthy blood donation. Antibodies against the NS3 (23%) and core (16.9%) antigens had the highest frequency among blood donors with positive/Reactive ELISA, respectively. The core antigen was the highest immunoreactive protein. A median correlation was found between OD in the ELISA test and the antibody profile in the RIBA test (
conclusionThe seroconversion in healthy blood donors is worrying in relation to the status of the disease in the community and its high incidence. Using Core and NS3 antigens assay can be helpful in screening and diagnosis or antigen detection might be the first next step following a Positive/Reactive antibody test. The use of serological algorithm in blood transfusion centers is questionable and our research has challenged the theory that blood donors with a history of blood donation are healthier in transmitting viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.